Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Multiple Myeloma × Anthracyclines × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Leukemia, Myeloid, Acute 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Neoplasms 1 Multiple Myeloma 1

Interventions

Dexamethasone 141 Bortezomib 79 Lenalidomide 77 Thalidomide 39 Melphalan 37 daratumumab 36 pomalidomide 32 Cyclophosphamide 29 carfilzomib 23 Calcium Dobesilate 23 Prednisone 18 Doxorubicin 13 elotuzumab 11 Filgrastim 11 ixazomib 10 isatuximab 9 Vincristine 9 Peripheral Blood Stem Cell Transplantation 9 belantamab mafodotin 8 Zoledronic Acid 8 dexamethasone acetate 7 Granulocyte Colony-Stimulating Factor 7 Epoetin Alfa 7 selinexor 5 Carmustine 5 fludarabine 4 Radiotherapy 4 Interferon-alpha 4 Etoposide 4 Denosumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02288741 2014-11-11

DSMM-II

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 3 Completed

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡